The stock of Telefonica Brasil SA (ADR) (NYSE:VIV) is a huge mover today! About 973,924 shares traded. Telefonica Brasil SA (ADR) (NYSE:VIV) has risen 1.30% since August 11, 2016 and is uptrending. It has underperformed by 7.51% the S&P500.The move comes after 8 months positive chart setup for the $23.63B company. It was reported on Mar, 20 by Barchart.com. We have $16.37 PT which if reached, will make NYSE:VIV worth $2.13B more.
Insys Therapeutics Incorporated (NASDAQ:INSY) had a decrease of 6.39% in short interest. INSY’s SI was 15.34 million shares in March as released by FINRA. Its down 6.39% from 16.38M shares previously. With 1.06 million avg volume, 15 days are for Insys Therapeutics Incorporated (NASDAQ:INSY)’s short sellers to cover INSY’s short positions. About 400,798 shares traded. Insys Therapeutics Inc (NASDAQ:INSY) has declined 46.22% since August 11, 2016 and is downtrending. It has underperformed by 55.03% the S&P500.
Among 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insys Therapeutics had 10 analyst reports since August 4, 2015 according to SRatingsIntel. On Tuesday, April 12 the stock rating was maintained by Jefferies with “Buy”. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Jefferies on Monday, October 10. The rating was downgraded by Zacks to “Buy” on Friday, August 14. JMP Securities maintained Insys Therapeutics Inc (NASDAQ:INSY) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $30 target. The rating was maintained by Jefferies on Wednesday, February 24 with “Buy”. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, December 21. Jefferies maintained the shares of INSY in report on Thursday, August 4 with “Buy” rating. Oppenheimer maintained Insys Therapeutics Inc (NASDAQ:INSY) on Tuesday, August 4 with “Hold” rating. The firm has “Buy” rating given on Thursday, April 14 by Janney Capital. The company was maintained on Thursday, September 22 by RBC Capital Markets.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The company has market cap of $730.18 million. The Firm develops and commercializes supportive care products. It has a 32.36 P/E ratio. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Since November 4, 2016, it had 1 buy, and 0 selling transactions for $107,489 activity. 10,000 shares valued at $107,489 were bought by MEYER STEVEN J on Friday, November 4.
Investors sentiment decreased to 0.86 in Q4 2016. Its down 0.37, from 1.23 in 2016Q3. It worsened, as 21 investors sold Insys Therapeutics Inc shares while 43 reduced holdings. 21 funds opened positions while 34 raised stakes. 27.44 million shares or 9.45% less from 30.31 million shares in 2016Q3 were reported. Deutsche Fincl Bank Ag has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY). Credit Agricole S A owns 312,000 shares. Blackrock Japan Com owns 1,093 shares. The Delaware-based Blackrock Advisors Limited Company has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Millennium Management Ltd Company owns 337,217 shares. Wellington Mgmt Gp Llp invested in 0% or 65,603 shares. Metropolitan Life New York holds 0% or 16,871 shares. National Bank & Trust Of Montreal Can has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Proshare Advsrs Lc reported 51,188 shares. Schneider Mngmt Corporation has 44,973 shares. Commerzbank Aktiengesellschaft Fi invested in 0% or 33,589 shares. 225,000 are held by Ascend Capital Lc. Piedmont Investment Advsr Ltd Liability Company reported 127 shares. Gam Ag owns 0.01% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 83,940 shares. State Common Retirement Fund invested in 22,700 shares.
Analysts await Telefonica Brasil SA (ADR) (NYSE:VIV) to report earnings on May, 5. They expect $0.18 EPS, down 5.26% or $0.01 from last year’s $0.19 per share. VIV’s profit will be $283.18 million for 20.86 P/E if the $0.18 EPS becomes a reality. After $0.22 actual EPS reported by Telefonica Brasil SA (ADR) for the previous quarter, Wall Street now forecasts -18.18% negative EPS growth.
Among 3 analysts covering Telefonica Brasil S.A (NYSE:VIV), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Telefonica Brasil S.A had 6 analyst reports since August 31, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, July 6 by Morgan Stanley. On Monday, August 31 the stock rating was upgraded by Morgan Stanley to “Overweight”. The stock of Telefonica Brasil SA (ADR) (NYSE:VIV) has “Overweight” rating given on Tuesday, October 6 by Barclays Capital.
